CONTACT
Cathryn Ingram
847-731-1520
[email protected]
Chicago — City of Hope®, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Walter Stadler, M.D., as the chief clinical officer at City of Hope Cancer Center Chicago. He joins City of Hope from University of Chicago Medical Center, where he served as an oncologist primarily focusing on advanced genitourinary disease. Stadler also spent over a decade in their Biological Sciences Division in various roles, including section chief for hematology/oncology, dean for Clinical Research, deputy director of the University of Chicago Comprehensive Cancer Center and senior advisor to the cancer center director.
Stadler will act as senior clinical leader for City of Hope Cancer Center Chicago, responsible for overall clinical care decisions and cancer care innovation. He will also serve patients as a medical oncologist specializing in advanced prostate, kidney, bladder and testicular disease. Additionally, he will hold an appointment as professor, Department of Medical Oncology & Therapeutics Research, with City of Hope.
“With Dr. Stadler at the helm of our clinical programs, we are strengthening our commitment to delivering the most advanced therapies, pioneering research, and personalized care that every patient deserves,” said Pete Govorchin, president of City of Hope Cancer Center Chicago. “His leadership will be instrumental as we implement standardized clinical pathways, enhance subspecialized diagnostic testing, and expand participation in national clinical trials—ensuring that more patients have access to the most advanced and effective cancer treatments available in the Midwest.”
Published in over 400 peer reviewed articles, editorials and book chapters, and over 300 abstracts and scientific presentations, Stadler is well known for his clinical research expertise, particularly in new drug developments in genitourinary cancers and enhanced access to clinical trials for underserved communities. He has led several investigator-initiated clinical trials for prostate cancer focused on decreasing toxicity and cost of care.
Board certified in medical oncology, Stadler’s clinical focus on GU cancer treatment and research is driven by a passion for providing patients with a higher quality of life and reducing disparities for cancer patients everywhere.
“City of Hope is a national leader in expanding access to leading-edge cancer care and clinical trials, and reducing disparities in treatment,” said Stadler. “I share those same goals, and together we are bringing the best cancer programs, brilliant clinical talent, innovative technology and progressive research to the patients and families who need it in our community.”
# # #
About City of Hope
City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked among the nation’s top cancer centers by U.S. News & World Report at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.